Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 14/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7418678 | 0.88 | GRM5 (0.85) | GRM5CYP1A2CYP2D6 | |
| SCHEMBL4137588 | 0.84 | GRM5 (1.00) | GRM5CYP1A2CYP2D6 | |
| SCHEMBL5650977 | 0.83 | GRM5 (0.72) | GRM5CYP1A2CYP2D6 | |
| SCHEMBL4466054 | 0.82 | GRM5 (0.76) | GRM5CYP1A2CYP2D6 | |
| SCHEMBL3353813 | 0.82 | GRM5 (0.68) | GRM5CYP1A2CYP2D6 | |
| SCHEMBL5653444 | 0.81 | GRM5 (0.73) | GRM5CYP1A2CYP2D6 | |
| SCHEMBL7387270 | 0.81 | GRM5 (0.74) | GRM5CYP1A2CYP2D6 | |
| SCHEMBL11966068 | 0.81 | GRM5 (1.00) | GRM5CYP1A2CYP2D6 | |
| SCHEMBL14573623 | 0.81 | GRM5 (1.00) | GRM5CYP1A2CYP2D6 | |
| SCHEMBL4144716 | 0.78 | GRM5 (1.00) | GRM5CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130123248-A1 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-05-16 | — | — | US | disclosed |
| US-20110306601-A1 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-15 | — | — | US | disclosed |
| US-20090192199-A1 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192199-A1 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | GRM1, GRM2, GRIN1 | GRM5 13/4885CYP1A2 4845/4885CYP2D6 4853/4885 |
| US-20110306601-A1 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | GRM1, GRM2, GRIN1 | GRM5 15/4885CYP1A2 4845/4885CYP2D6 4854/4885 |
| US-20130123248-A1 | PHARMACOLOGICAL MODULATION OF POSITIVE AMPA RECEPTOR MODULATOR EFFECTS ON NEUROTROPHIN EXPRESSION | GRM1, GRM2, GRIN1 | GRM5 15/4885CYP1A2 4845/4885CYP2D6 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.